NVIDIA backs Verily as healthcare AI firm extends March raise
What's the deal? VerilyDealroom has a profile for this one. Try Dealroom → has secured new investment from NVIDIA and existing backer CU Healthcare Innovation FundDealroom has a profile for this one. Try Dealroom → II, LP, the Dallas-based company announced on September 9, 2026. The funding extends a fundraising round Verily first opened in March.
What does Verily do? It is a data platform and technology company building AI-enabled precision health tools for research and care. Its flagship product, the Verily Pre Platform, helps healthcare organisations make their data AI-ready and deploy AI responsibly.
Who else is in? Verily's current investors include AlphabetDealroom has a profile for this one. Try Dealroom →, Series X CapitalDealroom has a profile for this one. Try Dealroom →, and UCHealthDealroom has a profile for this one. Try Dealroom →. NVIDIA joins as a new backer, while CU Healthcare Innovation Fund II adds to its existing stake.
Why now? The backing lands as Verily scales adoption of the Pre Platform and grows Verily Me, its patient engagement product. NVIDIA and Verily first announced a collaboration in October 2025.
What's the endgame? Researchers using the Pre Platform can tap NVIDIA AI libraries and frameworks, including NeMo, Parabricks, RAPIDS, and B200 GPUs. Using that stack, the two developed Forecast 1.0, a foundation model that combines genomics and electronic health record data to improve long-term health risk prediction.
"We are pleased to welcome NVIDIA as a new investor in Verily," said chairman and chief executive officer Stephen Gillett. He said the investments "accelerate our vision to build a trusted foundation for healthcare."
The signal: NVIDIA is deepening its footprint in healthcare AI by pairing capital with its compute stack, turning a technology partner into a shareholder — a model that ties chip demand to the data platforms building on it.
Read more: uk.finance.yahoo.com
Image credit: juhansonin
